Literature DB >> 23352642

The oncoprotein HBXIP up-regulates Skp2 via activating transcription factor E2F1 to promote proliferation of breast cancer cells.

Fuqiang Xu1, Xiaona You, Fabao Liu, Xiaohong Shen, Yuanqing Yao, Lihong Ye, Xiaodong Zhang.   

Abstract

Hepatitis B X-interacting protein (HBXIP) is a novel oncoprotein. In this study, we found that the expression levels of HBXIP were positively associated with those of S-phase kinase-associated protein 2 (Skp2) in clinical breast cancer tissues and cell lines. Moreover, we found that HBXIP was able to stimulate the promoter of Skp2 through binding to the -640/-443 region in Skp2 promoter involving activating E2F transcription factor 1 (E2F1). Skp2 plays crucial roles in HBXIP-enhanced proliferation of breast cancer cells in vitro and in vivo. We conclude that HBXIP up-regulates Skp2 via activating E2F1 to promote proliferation of breast cancer cells.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23352642     DOI: 10.1016/j.canlet.2013.01.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.

Authors:  Xiao-Lei Zhou; Xin Guo; Yu-Pin Song; Chong-Yue Zhu; Wei Zou
Journal:  Acta Pharmacol Sin       Date:  2017-11-30       Impact factor: 6.150

2.  lncRNA-HIT promotes cell proliferation of non-small cell lung cancer by association with E2F1.

Authors:  L Yu; F Fang; S Lu; X Li; Y Yang; Z Wang
Journal:  Cancer Gene Ther       Date:  2017-04-21       Impact factor: 5.987

3.  Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.

Authors:  Bo-Wen Liu; Tian-Jiao Wang; Lei-Lei Li; Lu Zhang; Yun-Xia Liu; Jin-Yan Feng; Yue Wu; Fei-Fei Xu; Quan-Sheng Zhang; Ming-Zhu Bao; Wei-Ying Zhang; Li-Hong Ye
Journal:  Acta Pharmacol Sin       Date:  2018-06-20       Impact factor: 6.150

4.  Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.

Authors:  Wei Zou; Xiangdong Ma; Hong Yang; Wei Hua; Biliang Chen; Guoqing Cai
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-05

5.  The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.

Authors:  Hang Li; Qian Liu; Zhen Wang; Runping Fang; Yu Shen; Xiaoli Cai; Yuen Gao; Yinghui Li; Xiaodong Zhang; Lihong Ye
Journal:  J Biol Chem       Date:  2015-07-30       Impact factor: 5.157

6.  HBXIP expression predicts patient prognosis in breast cancer.

Authors:  Daye Cheng; Bin Liang; Yunhui Li
Journal:  Med Oncol       Date:  2014-09-02       Impact factor: 3.064

7.  The nuclear import of oncoprotein hepatitis B X-interacting protein depends on interacting with c-Fos and phosphorylation of both proteins in breast cancer cells.

Authors:  Yingyi Zhang; Yu Zhao; Hang Li; Yinghui Li; Xiaoli Cai; Yu Shen; Hui Shi; Leilei Li; Qian Liu; Xiaodong Zhang; Lihong Ye
Journal:  J Biol Chem       Date:  2013-05-10       Impact factor: 5.157

8.  The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth.

Authors:  Fei-Fei Xu; Hui-Min Sun; Run-Ping Fang; Lu Zhang; Hui Shi; Xue Wang; Xue-Li Fu; Xian-Meng Li; Xu-He Shi; Yue Wu; Kai Ye; Wei-Ying Zhang; Li-Hong Ye
Journal:  Acta Pharmacol Sin       Date:  2021-04-06       Impact factor: 6.150

9.  Gene expression analysis of head and neck squamous cell carcinoma survival and recurrence.

Authors:  Xu Zhi; Katarzyna Lamperska; Paweł Golusinski; Nicholas J Schork; Lukasz Luczewski; Tomasz Kolenda; Wojciech Golusinski; Michal M Masternak
Journal:  Oncotarget       Date:  2015-01-01

10.  The oncoprotein HBXIP promotes glucose metabolism reprogramming via downregulating SCO2 and PDHA1 in breast cancer.

Authors:  Fabao Liu; Weiying Zhang; Xiaona You; Yunxia Liu; Yinghui Li; Zhen Wang; Yue Wang; Xiaodong Zhang; Lihong Ye
Journal:  Oncotarget       Date:  2015-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.